Related Experiment Video
Updated: Jul 4, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma
M Santisteban1, J L Pérez-Gracia, J Ceballos
1Medical Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain. santisteban.marta@mayo.edu
Abstract:
We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
